 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ZX-101A / Zenshine Pharma
Trial completion, Enrollment change: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Nov 4, 2024
P1/2, N=40, Completed, Sponsor: Nanjing Zenshine Pharmaceuticals
Recruiting --> Completed | N=70 --> 40
- | ZX-101A / Zenshine Pharma
Enrollment change, Trial completion date, Trial termination, Metastases: Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies (clinicaltrials.gov) - Oct 21, 2022
P1/2, N=6, Terminated, Sponsor: Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Recruiting --> Completed | N=70 --> 40 N=66 --> 6 | Trial completion date: Jan 2023 --> Jul 2022 | Recruiting --> Terminated; Study terminated early due to business decision.
- ZX-101A / Zenshine Pharma
A Phase 1/2a Study of a PI3Kδγ dual inhibitor ZX-101A in patients with advanced solid tumors (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6709;
P1/2
Part 2 dose expansion will evaluate ZX-101A activity in up to three disease-specific cohorts. Inclusion of combination therapy is planned after obtaining the initial clinical assessment of ZX-101A on its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients.
- |||| ZX-101A / Zenshine Pharma
New P1/2 trial: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Mar 8, 2022
P1/2, N=70, Recruiting, Sponsor: Nanjing Zenshine Pharmaceuticals
- |||| ZX-101A / Zenshine Pharma
New P1/2 trial, Monotherapy, Metastases: A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors (clinicaltrials.gov) - Feb 28, 2022
P1/2, N=76, Not yet recruiting, Sponsor: Nanjing Zenshine Pharmaceuticals
- ZX-101 / Zenshine Pharma
[VIRTUAL] A next-generation PI3Kδ/γ inhibitor, ZX-101A inhibiting solid tumor growth by enhancing anti-tumor immunity () - Mar 13, 2021 - Abstract #AACR2021AACR_4419;
Its absorption, distribution, metabolism, and excretion (ADME) and safety profile, through a series of preclinical in vitro and in vivo studies, supported the ZX-101A clinical development. These results suggested ZX-101A as a potential immunotherapeutic agent to appropriate solid tumor types.
- Copiktra (duvelisib) / Secura Bio, Yakult Honsha
[VIRTUAL] A phase 1/2a, dose-escalation and dose-expansion study of ZX-101A in patients with relapsed/resistant or refractory advanced hematologic malignancies () - Mar 11, 2021 - Abstract #AACR2021AACR_3890;
P1/2
Part 2 dose expansion will evaluate ZX-101A activity in up to three disease-specific cohorts (CLL/SLL, indolent NHL, and based on emerging data from Part 1, Peripheral T-cell lymphoma may be included). Inclusion of a cohort of combination therapy is planned.
- ||| ZX-101A / Zenshine Pharma
Enrollment open, Trial initiation date, Metastases: Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies (clinicaltrials.gov) - Jan 11, 2021
P1/2, N=66, Recruiting, Sponsor: Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Inclusion of a cohort of combination therapy is planned. Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Jan 2021
- | ZX-101A / Zenshine Pharma
New P1/2 trial, Metastases: Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies (clinicaltrials.gov) - Aug 7, 2020
P1/2, N=66, Not yet recruiting, Sponsor: Hangzhou Zenshine Pharmaceuticals Co., Ltd.